Search Results

You are looking at 31 - 40 of 503 items for :

  • "Adjuvant therapy" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Mutation Testing and Adjuvant Systemic Therapy in Cutaneous Melanoma

Anthony J. Olszanski

Patients with stage III melanoma are at high risk for disease recurrence, but adjuvant therapy—including targeted therapy and immunotherapy—may prevent or delay relapse, according to Anthony J. Olszanski, MD, RPh, Associate Professor and Vice Chair

Full access

Multidisciplinary Management of Early-Stage Rectal Cancer

John G. Phillips, Theodore S. Hong, and David P. Ryan

management of patients with rectal cancer. Discuss the role of adjuvant therapy in the management of rectal cancer. Patients with AJCC stage II (invasion through the muscularis layers) and III (node-positive) rectal cancer are at high risk for both

Full access

NCCN Guidelines Updates: Pancreatic Cancer

Margaret A. Tempero

Panel Adds to Pancreatic Cancer Recommendations For the first time in decades, advances in diagnostics and adjuvant therapies appear to be improving outcomes in pancreatic cancer. These advances are reflected in additions to the NCCN Clinical

Full access

VATS Versus Open Surgery for Lung Cancer Resection: Moving Toward a Minimally Invasive Approach

Jacob Klapper and Thomas A. D’Amico

. The thoracoscopic approach is oncologically equivalent to thoracotomy, while resulting in fewer complications, improved quality of life, shorter length of stay, and superior compliance with adjuvant therapies. 6 – 8 Oncologic Outcomes The

Full access

Principles of Management of Patients With Ampullary Adenocarcinoma

Presented by: Stephen W. Behrman

, patients are categorized based on the predominant subtype. Although the prognostic value of subtyping relative to adjuvant therapy and neoadjuvant therapy remains unclear, Dr. Behrman underscored the importance of subtyping for future therapeutic

Full access

Counterpoint: The Case Against Adjuvant High-Dose Interferon-α for Melanoma Patients

Paul B. Chapman

analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system . J Clin Oncol 2001 ; 19 : 3622 – 3634 . 2 Kirkwood JM Strawderman MH Ernstoff MS . Interferon alfa-2b adjuvant therapy of high

Full access

Comparison of Treatment Strategies for Patients With Clinical Stage T1–3/N2 Lung Cancer

Ya-Fu Cheng, Wei-Heng Hung, Heng-Chung Chen, Ching-Yuan Cheng, Ching-Hsiung Lin, Sheng-Hao Lin, and Bing-Yen Wang

offer surgical treatment and more likely to use induction therapy before resection, whereas European surgeons preferred to offer OP followed by adjuvant therapy in select cases of N2 disease. Different therapeutic methods were compared in previous

Full access

Updates to the Management of Kidney Cancer

Eric Jonasch

Center, and Vice Chair of the NCCN Guidelines Panel for Kidney Cancer, as he introduced his presentation at the NCCN 23rd Annual Conference. Adjuvant Therapy Five adjuvant therapy trials have been conducted in renal cell carcinoma (RCC). The ASSURE

Full access

Central Nervous System: Notable Developments in the Management of Primary and Recurrent Gliomas

Louis Burt Nabors

different: for RTOG 9402, neoadjuvant therapy consisted of PCV chemotherapy before RT, and in EORTC 26951 adjuvant therapy consisted of PCV chemotherapy after RT. However, toxicity from the PCV regimen was an issue in both studies. “A lot of patients did not

Full access

Impact of the First Generation of Children’s Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor

Jeffrey S. Dome, Elizabeth A. Mullen, David B. Dix, Eric J. Gratias, Peter F. Ehrlich, Najat C. Daw, James I. Geller, Murali Chintagumpala, Geetika Khanna, John A. Kalapurakal, Lindsay A. Renfro, Elizabeth J. Perlman, Paul E. Grundy, and Conrad V. Fernandez

patients with very low risk WT, as described in the text, who were candidates to receive no adjuvant therapy. The structure of the AREN ‘0’ studies is depicted in Figure 2 . An expanded menu of biologic and clinical prognostic factors, including